Supernus Pharmaceuticals SUPN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $776.83M+16.3% | $718.95M+8.6% | $681.54M+4.5% | $665.13M+5.5% | $668M+11.8% | ||
| $82.19M+6.2% | $74.56M-4.3% | $77.65M+8.7% | $76.27M+3.8% | $77.36M+1.0% | ||
| $694.64M+17.6% | $644.39M+10.4% | $603.89M+4.0% | $588.85M+5.8% | $590.64M+13.4% | ||
| 89.4%+1.0pp | 89.6%+1.4pp | 88.6%-0.4pp | 88.5%+0.2pp | 88.4%+1.2pp | ||
| $118.75M+7.2% | $106.24M-2.4% | $107.06M+3.4% | $106.73M+9.9% | $110.79M+16.2% | ||
| $520.79M+60.2% | $485.56M+51.0% | $442.58M+36.8% | $332.66M-1.1% | $325.01M-3.6% | ||
| $837.19M+41.1% | $781.24M+34.7% | $718.48M+21.2% | $600.99M-0.4% | $593.43M-2.9% | ||
| -$60.36M-181% | -$62.28M-176% | -$36.94M-162% | $64.14M+141% | $74.56M+648% | ||
| -7.8%-18.9pp | -8.7%-21.0pp | -5.4%-14.5pp | 9.6%+5.4pp | 11.2%+13.4pp | ||
| $11.21M-35.0% | $13.25M-18.2% | $16.21M+22.7% | $18.03M+65.9% | $17.23M+127% | ||
| -$49.15M-154% | -$49.03M-150% | -$20.73M-129% | $82.16M+120% | $91.8M+1,629% | ||
| —— | —— | -$1.62M— | $17.67M— | $29.88M— | ||
| -$29.02M-147% | -$38.55M-152% | -$19.12M-132% | $64.5M+1,131% | $61.91M+499% | ||
| -3.7%-13.0pp | -5.4%-16.5pp | -2.8%-12.0pp | 9.7%+8.9pp | 9.3%+11.9pp | ||
| -$0.51-146% | -$0.68-152% | -$0.34-132% | $1.15+1,178% | $1.11+483% | ||
| $36.95M-76.1% | $29.28M-81.9% | $48.45M-66.0% | $144.82M+29.8% | $154.61M+117% | ||
| 4.8%-18.4pp | 4.1%-20.4pp | 7.1%-14.7pp | 21.8%+4.1pp | 23.1%+11.2pp | ||
| -$60.36M-181% | -$62.28M-176% | -$36.94M-162% | $64.14M+141% | $74.56M+648% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Supernus Pharmaceuticals's revenue?
- Supernus Pharmaceuticals (SUPN) generated $776.8M in revenue over the trailing twelve months, up 16.3% year over year.
- Is Supernus Pharmaceuticals profitable?
- Supernus Pharmaceuticals is not currently profitable: it reported a net loss of $29.0M over the trailing twelve months, a -3.7% net margin.
- What are Supernus Pharmaceuticals's profit margins?
- Gross margin is 89.4% and operating margin is -7.8%, with a -3.7% net margin.
- What is Supernus Pharmaceuticals's earnings per share?
- Supernus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.51.
- Where does Supernus Pharmaceuticals's income statement data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
